Study title: A a dose-escalation Phase I study in children and adolescent with relapsed or refractory leukemia.
Type of medicine: Centrally authorised medicines | |||||
Therapeutic area: Neoplasms | |||||
Brands: Please see report | |||||
MAH holders: Please see report, Please see report, Please see report, Please see report, Please see report, Please see report | |||||
Assessment: | |||||
Active substance: arsenic trioxide | |||||
ATC code: L01XX27 | |||||
Document link: Trisenox T99080.xls | |||||
Document date: 2011-09-19 | |||||
Study number: T99080 | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |